India, June 26 -- What's driving the momentum in the following stocks?
Vor Bio, Inc. (VOR) has secured ex-Greater China rights from RemeGen Co., Ltd. to develop and commercialize Telitacicept, a novel dual-target fusion protein approved in China for generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis. RemeGen is entitled to receive from Vor Bio an initial payment of $125 million, consisting of an upfront payment of $45 million plus $80 million of warrants, potential regulatory and commercial milestones exceeding $4 billion, as well as tiered royalties. Vor has also entered into a securities purchase agreement for a private placement in public equity financing that is expected to result in gross proceeds of...